<p>Eledon Pharmaceuticals, Inc.（納斯達克代碼：ELDN - 獲取免費報告）在三月份的空頭頭寸顯著增長。截至 3 月 13 日，空頭頭寸總計為 8,417,915 股，比 2 月 26 日的 6,458,931 股增長了 30.3%。該公司約有 12.7% 的股票被做空。根據平均每日交易量 1,292,590 股，目前的空頭頭寸比率為 6.5 天。</p>
<p>獲取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
<h2>Eledon Pharmaceuticals 股票表現</h2>
<p>在週五的交易中，ELDN 股票下跌 0.13 美元，報 2.83 美元。該公司交易了 864,502 股，較其平均交易量 1,556,412 股有所減少。該公司的 50 日簡單移動平均線為 2.44 美元，200 日簡單移動平均線為 2.35 美元。Eledon Pharmaceuticals 的 12 個月低點為 1.35 美元，12 個月高點為 4.60 美元。該公司的市值為 2.1466 億美元，市盈率為-5.44，貝塔值為 0.84。</p>
<p>Eledon Pharmaceuticals（納斯達克代碼：ELDN - 獲取免費報告）最近於 3 月 19 日星期四發佈了季度財報。該公司報告每股收益為（0.10 美元），超出市場共識預期的（0.20 美元）0.10 美元。分析師平均預測 Eledon Pharmaceuticals 在當前財年將發佈每股收益為-0.81 美元。</p>
<h2>分析師評級升級與降級</h2>
<p>另外，Weiss Ratings 在 12 月 29 日的報告中重申了對 Eledon Pharmaceuticals 股票的 “賣出（d-）” 評級。三位分析師給予該股票買入評級，一位給予持有評級，一位給予賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價為 9.67 美元。</p>
<p><strong>閲讀我們關於 ELDN 的最新股票報告</strong></p>
<h2>Eledon Pharmaceuticals 的機構交易</h2>
<p>幾家對沖基金和其他機構投資者最近調整了對 ELDN 的持股。洛克菲勒資本管理公司在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 95.5%。洛克菲勒資本管理公司現在擁有 71,666 股該公司的股票，價值 108,000 美元，此前在上個季度購買了額外的 35,000 股。Kera Capital Partners Inc.在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 54.3%。Kera Capital Partners Inc.現在擁有 39,770 股該公司的股票，價值 60,000 美元，此前在上個季度收購了額外的 14,000 股。Virtu Financial LLC 在第四季度獲得了 Eledon Pharmaceuticals 的新頭寸，價值 39,000 美元。XTX Topco Ltd 在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 867.1%。XTX Topco Ltd 現在擁有 124,247 股該公司的股票，價值 188,000 美元，此前在上個季度購買了額外的 111,399 股。最後，Zimmer Partners LP 在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 30.6%。Zimmer Partners LP 現在擁有 2,384,228 股該公司的股票，價值 3,600,000 美元，此前在上個季度購買了額外的 559,228 股。目前 56.77% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Eledon Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Eledon Pharmaceuticals, Inc.（納斯達克代碼：ELDN）是一家臨牀階段的生物製藥公司，專注於發現和開發針對平滑肌功能障礙疾病的治療方法。該公司利用專有的離子通道調節平台，識別和優化小分子化合物，以恢復或抑制平滑肌活動，旨在解決胃腸、肝臟和心血管疾病。</p>
<p>Eledon 的產品管線包括多個針對高未滿足需求指徵的臨牀前和早期臨牀項目。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Eledon Pharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Eledon Pharmaceuticals 嗎？</h2>
<p>在你考慮 Eledon Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Eledon Pharmaceuticals 並不在名單上。</p>
<p>雖然 Eledon Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>查看這五隻股票</p>

ELDN

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Eledon Pharmaceuticals, Inc.（納斯達克代碼：ELDN）在三月份的空頭頭寸增加了 30.3%，總計達到 8,417,915 股。這大約佔公司股票的 12.7%，根據平均每日交易量 1,292,590 股計算，空頭頭寸比率為 6.5 天。該股票交易價格下跌至$2.83，市值為 2.1466 億美元。分析師對 ELDN 的共識評級為 “持有”，平均目標價格為$9.67。機構投資者持有 56.77% 的股份，反映出對該公司的顯著興趣</p>

<p>Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a significant growth in short interest in March. As of March 13th, there was short interest totaling 8,417,915 shares, a growth of 30.3% from the February 26th total of 6,458,931 shares. Approximately 12.7% of the company's stock are short sold. Based on an average daily volume of 1,292,590 shares, the short-interest ratio is currently 6.5 days.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc.（納斯達克代碼：ELDN - 獲取免費報告）在三月份的空頭頭寸顯著增長。截至 3 月 13 日，空頭頭寸總計為 8,417,915 股，比 2 月 26 日的 6,458,931 股增長了 30.3%。該公司約有 12.7% 的股票被做空。根據平均每日交易量 1,292,590 股，目前的空頭頭寸比率為 6.5 天。</p>
</div><p>Get <strong>Eledon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Eledon Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 股票表現</h2>
</div><p>Shares of ELDN stock traded down $0.13 during trading on Friday, hitting $2.83. 864,502 shares of the company were exchanged, compared to its average volume of 1,556,412. The business's 50-day simple moving average is $2.44 and its 200 day simple moving average is $2.35. Eledon Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.60. The firm has a market capitalization of $214.66 million, a price-to-earnings ratio of -5.44 and a beta of 0.84.</p>
<div class="lb-trans"><p>在週五的交易中，ELDN 股票下跌 0.13 美元，報 2.83 美元。該公司交易了 864,502 股，較其平均交易量 1,556,412 股有所減少。該公司的 50 日簡單移動平均線為 2.44 美元，200 日簡單移動平均線為 2.35 美元。Eledon Pharmaceuticals 的 12 個月低點為 1.35 美元，12 個月高點為 4.60 美元。該公司的市值為 2.1466 億美元，市盈率為-5.44，貝塔值為 0.84。</p>
</div><p>Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.10. On average, equities analysts forecast that Eledon Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals（納斯達克代碼：ELDN - 獲取免費報告）最近於 3 月 19 日星期四發佈了季度財報。該公司報告每股收益為（0.10 美元），超出市場共識預期的（0.20 美元）0.10 美元。分析師平均預測 Eledon Pharmaceuticals 在當前財年將發佈每股收益為-0.81 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級升級與降級</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Eledon Pharmaceuticals in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $9.67.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 29 日的報告中重申了對 Eledon Pharmaceuticals 股票的 “賣出（d-）” 評級。三位分析師給予該股票買入評級，一位給予持有評級，一位給予賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價為 9.67 美元。</p>
</div><p><strong>Read Our Latest Stock Report on ELDN</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ELDN 的最新股票報告</strong></p>
</div><h2>Institutional Trading of Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 的機構交易</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of ELDN. Rockefeller Capital Management L.P. boosted its position in Eledon Pharmaceuticals by 95.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 71,666 shares of the company's stock valued at $108,000 after purchasing an additional 35,000 shares during the last quarter. Kera Capital Partners Inc. grew its position in Eledon Pharmaceuticals by 54.3% in the fourth quarter. Kera Capital Partners Inc. now owns 39,770 shares of the company's stock worth $60,000 after acquiring an additional 14,000 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Eledon Pharmaceuticals during the 4th quarter worth $39,000. XTX Topco Ltd increased its stake in shares of Eledon Pharmaceuticals by 867.1% during the 4th quarter. XTX Topco Ltd now owns 124,247 shares of the company's stock worth $188,000 after purchasing an additional 111,399 shares during the last quarter. Finally, Zimmer Partners LP raised its holdings in shares of Eledon Pharmaceuticals by 30.6% during the 4th quarter. Zimmer Partners LP now owns 2,384,228 shares of the company's stock valued at $3,600,000 after purchasing an additional 559,228 shares in the last quarter. 56.77% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近調整了對 ELDN 的持股。洛克菲勒資本管理公司在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 95.5%。洛克菲勒資本管理公司現在擁有 71,666 股該公司的股票，價值 108,000 美元，此前在上個季度購買了額外的 35,000 股。Kera Capital Partners Inc.在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 54.3%。Kera Capital Partners Inc.現在擁有 39,770 股該公司的股票，價值 60,000 美元，此前在上個季度收購了額外的 14,000 股。Virtu Financial LLC 在第四季度獲得了 Eledon Pharmaceuticals 的新頭寸，價值 39,000 美元。XTX Topco Ltd 在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 867.1%。XTX Topco Ltd 現在擁有 124,247 股該公司的股票，價值 188,000 美元，此前在上個季度購買了額外的 111,399 股。最後，Zimmer Partners LP 在第四季度將其在 Eledon Pharmaceuticals 的持股增加了 30.6%。Zimmer Partners LP 現在擁有 2,384,228 股該公司的股票，價值 3,600,000 美元，此前在上個季度購買了額外的 559,228 股。目前 56.77% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Eledon Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Eledon Pharmaceuticals, Inc NASDAQ: ELDN is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc.（納斯達克代碼：ELDN）是一家臨牀階段的生物製藥公司，專注於發現和開發針對平滑肌功能障礙疾病的治療方法。該公司利用專有的離子通道調節平台，識別和優化小分子化合物，以恢復或抑制平滑肌活動，旨在解決胃腸、肝臟和心血管疾病。</p>
</div><p>Eledon's pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.</p>
<div class="lb-trans"><p>Eledon 的產品管線包括多個針對高未滿足需求指徵的臨牀前和早期臨牀項目。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Eledon Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Eledon Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Eledon Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Eledon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Eledon Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Eledon Pharmaceuticals 並不在名單上。</p>
</div><p>While Eledon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eledon Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Eledon Pharmaceuticals, Inc.（NASDAQ:ELDN）的空頭頭寸增加了 30.3%